Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41409-025-02681-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers.
Transfus Apher Sci
September 2025
Terumo Blood and Cell Technologies, Zaventem, Belgium. Electronic address:
Background: This study, conducted among collection and transplant centers in France, Germany, Japan, the United Kingdom (UK), and the United States (USA), aimed to better understand current trends, challenges, and future directions in cell collection and apheresis practices, focusing on the Spectra Optia™ Apheresis System.
Methods: This cross-sectional study was conducted from July to November 2023 among facilities using the Spectra Optia™ Apheresis System, which could also be using other comparable cell collection technologies, with expertise in cell collection and therapeutics. Respondents completed an online questionnaire.
Mob-Marly: A Latin American experience in hematopoietic stem cell mobilization for autologous transplantation.
Transfus Apher Sci
August 2025
Apheresis and Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, ICAMS, Hospital Clínic, IDIPAPS, UB, Barcelona, Spain.
Background: Hematopoietic stem cell (HSC) mobilization is a critical step in autologous transplantation for patients with multiple myeloma and lymphoma. While several risk factors for mobilization failure have been identified, real-world data from Latin America remain limited. This study aimed to describe mobilization outcomes and associated factors in a transplant center in Colombia.
View Article and Find Full Text PDFMobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab.
Bone Marrow Transplant
August 2025
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024.
Transplant Cell Ther
August 2025
Division of Blood and Marrow Transplant and Cellular Therapy, Stanford University School of Medicine, Stanford, CA. Electronic address:
Background: Autologous stem cell transplantation (ASCT) remains a standard component of frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). CD38 monoclonal antibodies (mAbs), such as daratumumab and isatuximab, have been incorporated into induction regimens and are associated with deeper responses. However, their impact on hematopoietic stem cell mobilization is unclear, particularly in real-world practice.
View Article and Find Full Text PDFTead1a Initiates Transcriptional Priming Through the TEAD1a/YAP-Notch1-Spi1/Cebpα Axis to Promote Neutrophil Fate.
Adv Sci (Weinh)
August 2025
Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Clinical neutropenia, a blood disorder marked by faulty neutrophil production, resists effective treatment due to developmental bottlenecks in granulopoiesis. While the current therapy, such as granulocyte colony-stimulating factor (G-CSF), boosts neutrophil counts, its late-stage action mobilizes dysfunctional cells, underscoring the need for early-lineage therapeutic interventions. Leveraging zebrafish models, we found that transcriptional enhanced associate domain 1a (TEAD1a) initiates transcriptional priming to govern neutrophil lineage specification preceding hematopoietic stem cell formation.
View Article and Find Full Text PDF